Skip to main content
. 2017 Oct 16;127(11):4179–4192. doi: 10.1172/JCI91258

Figure 1. C-KIT inhibitor dasatinib suppresses cell proliferation and the activation of the MNK/eIF4E axis in KIT-mutant melanomas.

Figure 1

(A) Western blot analysis of phospho-MNK1 (p-MNK1), MNK1, phospho-eIF4E (p-eIF4E), and eIF4E in a panel of melanoma cell lines. (B) Cell proliferation was assessed by SRB staining, 72 hours after vehicle (DMSO) or 10 nM dasatinib treatment in HBL, MM61, MM111, and M230 melanoma cell lines. (C) Western blot analysis of phospho–C-KIT (p-C-KIT), C-KIT, p-eIF4E, eIF4E, p-MNK1, and MNK1 in HBL, MM111, MM61, and M230 melanoma cell lines, following a 24-hour dasatinib treatment. (D) Cell proliferation was assessed by SRB staining, 96 hours after transfection with KIT siRNAs. (E) Western blot analysis of p-C-KIT, C-KIT, p-eIF4E, eIF4E, p-MNK1, and MNK1 in HBL, MM111, and M230 cell lines transfected with KIT siRNAs, at the indicated time points. (B and D) Data represent the mean ± SD, n = 3. **P < 0.01 by 2-way ANOVA. (A, C, and E) GAPDH used as loading control.